250588-64-8

Upstream product

• 773837-37-9 sodium cyanide 
• 6698-46-0 5-O-benzoyl-1,2-O-isopropylidene-α-D-ribofuranos-3-ulose 
• 143-33-9 sodium cyanide 

Downstream Products

• 142102-82-7 <1-<2',5'-bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl>-3-N-(3-methyl-2-butenyl)thymine>-3'-spiro-5''-(4''-amino-1'',2''-oxathiole 2'',2''-dioxide) 
• 142102-81-6 <1-<2',5'-bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl>-3-N-allylthymine>-3'-spiro-5''-(4''-amino-1'',2''-oxathiole 2'',2''-dioxide) 
• 142102-80-5 <1-<2',5'-bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl>-3-N-ethylthymine>-3'-spiro-5''-(4''-amino-1'',2''-oxathiole 2'',2''-dioxide) 
• 142102-75-8 <1-<2',5'-bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl>-5-ethyluracil>-3'-spiro-5''-(4''-amino-1'',2''-oxathiole 2'',2''-dioxide) 
• 142102-83-8 <1-<2',5'-bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl>-3-N-allyluracil>-3'-spiro-5''-(4''-amino-1'',2''-oxathiole 2'',2''-dioxide) 
• 142102-79-2 TSAO-m3T 
• 142102-73-6 1-(2'-O-acetyl-5'-O-benzoyl-3'-C-cyano-3'-O-mesyl-β-D-ribofuranosyl)-5-ethyluracil 
• 142102-74-7 <1-(2'-O-acetyl-5'-O-benzoyl-β-D-ribofuranosyl)thymine>-3'-spiro-5''-(4''-amino-1'',2''-oxathiole 2'',2''-dioxide) 
• 142102-77-0 TSAO-m5C 
• 141845-83-2 {1-[2',5'-bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]uracil}-3'-spiro-5''-(4''-amino-1'',2''-oxathiole 2'',2''-dioxide) 
• 142102-78-1 <1-<2',5'-bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl>cytosine>-3'-spiro-5''-(4''-amino-1'',2''-oxathiole 2'',2''-dioxide) 
• 142102-71-4 1-(2'-O-acetyl-5'-O-benzoyl-3'-C-cyano-3'-O-mesyl-β-D-ribofuranosyl)thymine 

Relevant academic research and scientific papers

Preparation of spiro[4.4]oxaphospholene and -azaphospholene systems from carbohydrate templates

Introduction of a spiro-phosphorus cycle in position 3 of monosaccharidic derivatives was studied starting from cyanohydrin or aminonitrile A. A two-step procedure involving (i) phosphonylation and (ii) carbanion-mediated phosphonate intramolecular cyclization (denoted CPIC) was used. The necessity of having an electron-withdrawing group α to the phosphorus atom in order to avoid undesired reactions was demonstrated.

Synthesis, anti-HIV-1 activity, and modeling studies of N-3 Boc TSAO compound

The synthesis and the biological evaluation of the anti-HIV-1 activity of TSAO-Boc3T (8) are described. The computational analysis showed that the N-3 Boc group promotes new interactions in the binding site of the enzyme leading to a good inhib

TSAO analogues. Stereospecific synthesis and anti-HIV-1 activity of 1- [2',5'-bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]-3'-spiro-5''-(4''- amino-1'',2''-oxathiole 2'',2''-dioxide) pyrimidine and pyrimidine-modified nucleosides

Several analogues of a new lead for anti-HIV-1 agents [1-[2',5'-bis-O- (tert-butyldimethylsilyl)-β-D-ribofuranosyl]-thymine]-3'-spiro-5''-(4''- amino-1'',2''-oxathiole 2'',2''-dioxide) (TSAO) modified at positions N-3, O- 4 and C-5 of the thymine moiety,